A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Yukinobu Watanabe; Masahiro Ogawa; Yu Tamura; Seiichiro Suda; Masahiro Kaneko; Mariko Kumagawa; Midori Hirayama; Naoki Matsumoto; Toshiki Yamamoto; Mitsuhiko Moriyama

doi:10.1177/23247096211058489

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Yukinobu Watanabe, Masahiro Ogawa, Yu Tamura, Seiichiro Suda, Masahiro Kaneko, Mariko Kumagawa, Midori Hirayama, Naoki Matsumoto, Toshiki Yamamoto, Mitsuhiko Moriyama

School of Medicine

Nihon University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Original language	English
Journal	Journal of Investigative Medicine High Impact Case Reports
Volume	9
DOIs	https://doi.org/10.1177/23247096211058489
Publication status	Published - Nov 2021

Keywords

Hepatocellular carcinoma
atezolizumab
bevacizumab
immune checkpoint inhibitor
pseudoprogression

Access to Document

10.1177/23247096211058489

Cite this

@article{e26c66bfa62f4630bef6631d05c697f9,

title = "A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab",

abstract = "A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.",

keywords = "Hepatocellular carcinoma, atezolizumab, bevacizumab, immune checkpoint inhibitor, pseudoprogression",

author = "Yukinobu Watanabe and Masahiro Ogawa and Yu Tamura and Seiichiro Suda and Masahiro Kaneko and Mariko Kumagawa and Midori Hirayama and Naoki Matsumoto and Toshiki Yamamoto and Mitsuhiko Moriyama",

note = "Publisher Copyright: {\textcopyright} 2021 American Federation for Medical Research.",

year = "2021",

month = nov,

doi = "10.1177/23247096211058489",

language = "English",

volume = "9",

journal = "Journal of Investigative Medicine High Impact Case Reports",

issn = "2324-7096",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

AU - Watanabe, Yukinobu

AU - Ogawa, Masahiro

AU - Tamura, Yu

AU - Suda, Seiichiro

AU - Kaneko, Masahiro

AU - Kumagawa, Mariko

AU - Hirayama, Midori

AU - Matsumoto, Naoki

AU - Yamamoto, Toshiki

AU - Moriyama, Mitsuhiko

PY - 2021/11

Y1 - 2021/11

N2 - A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

AB - A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

KW - Hepatocellular carcinoma

KW - atezolizumab

KW - bevacizumab

KW - immune checkpoint inhibitor

KW - pseudoprogression

UR - http://www.scopus.com/inward/record.url?scp=85120329061&partnerID=8YFLogxK

U2 - 10.1177/23247096211058489

DO - 10.1177/23247096211058489

M3 - Article

C2 - 34845921

AN - SCOPUS:85120329061

SN - 2324-7096

VL - 9

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

ER -

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this